Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.07.004
<div><h3>Objective</h3><div>To examine trends, characteristics, and outcomes of donor oocyte embryo transfer cycles by original oocyte and resultant embryo state and determine whether oocyte state (fresh or frozen) is differentially associated with clinical pregnancy, live birth, and term, healthy birthweight neonates among singleton live births.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>National study.</div></div><div><h3>Patient(s)</h3><div>Patients undergoing donor oocyte embryo transfer cycles in the United States reporting to the National Assisted Reproductive Technology Surveillance System from 2013 to 2020<sub>.</sub></div></div><div><h3>Intervention(s)</h3><div>Original donor oocyte and resultant embryo state (fresh or frozen).</div></div><div><h3>Main Outcome Measure(s)</h3><div>Annual numbers and proportions of total donor oocyte embryo transfer cycles stratified by oocyte and embryo state and single embryo transfer cycles resulting in the live birth of term (≥37 weeks gestation), healthy birthweight (≥2,500 g) singletons during 2013–2020. Rates of live birth and term, healthy birthweight neonates among singleton live births for 2018–2020 are also reported. Relative risks examine associations between donor oocyte state and live birth and term, healthy birthweight neonates among singleton live births resulting from donor oocyte embryo transfer cycles.</div></div><div><h3>Result(s)</h3><div>From 2013 to 2020, there were 135,085 donor oocyte embryo transfer cycles, of which the proportions increased for frozen embryos (42.3%–76.6%), fresh embryos using frozen donor oocytes (19.9%–68.3%) and single embryo transfers (36.4%–85.5%). During 2018–2020, there were 48,679 donor oocyte embryo transfer cycles. Rates of live birth were lower with frozen compared with fresh donor oocytes for both fresh (46.2%, 55.9%; adjusted relative risk [aRR], 0.83; 95% confidence interval [CI], 0.79–0.87) and frozen (41.3%, 45.8%; aRR, 0.94; 95% CI, 0.91–0.98) embryo transfer cycles. Among singleton live births, rates of delivering a term, healthy birth weight neonate were similar for frozen compared with fresh donor oocyte transfer cycles among fresh (77.3%, 77.2%; aRR, 1.01; 95% CI, 0.98–1.03) and frozen (75.6%, 75.1%; aRR, 1.02; 95% CI, 0.99–1.04) embryos.</div></div><div><h3>Conclusion(s)</h3><div>In this national study of donor oocyte embryo transfer cycles, frozen embryo transfers, fresh embryo transfers using frozen oocytes, and single embryo transfers increased. Although frozen compared with fresh oocytes were associated with a slightly reduced rate of live birth, rates of term, healthy birthweight neonates among singleton live births were comparable between donor oocyte states.</div></div><div><div>Tendencias y resultados de los ciclos de ovocitos de donantes frescos y congelados en los Estados Unidos</div></div><div><h3>Objetivo</h3><div>Examinar las tendencias, características y resultados de lo
目的按照原始卵母细胞和胚胎状态研究供体卵母细胞胚胎移植周期的趋势、特征和结果，并确定卵母细胞状态（新鲜或冷冻）是否与临床妊娠、活产以及单胎活产中足月正常出生体重新生儿有不同关系：设计：回顾性队列研究 对象：接受供体卵母细胞胚胎移植的患者：2013-2020年期间向美国国家辅助生殖技术监测系统（NASS）报告的接受供体卵母细胞胚胎移植周期的患者：原始供体卵母细胞和胚胎状态（新鲜或冷冻） 主要结局指标：2013-2020 年期间，按卵母细胞和胚胎状态分层的总供体卵母细胞胚胎移植周期和单胚胎移植周期导致足月（妊娠≥37 周）、正常出生体重（≥2500 克）单胎活产的年度数量和比例。还报告了 2018-2020 年单胎活产中的活产率和足月、正常出生体重新生儿的比率。相对风险（RR）考察了供体卵母细胞状态与供体卵母细胞胚胎移植周期导致的单胎活产中的活产率和足月、正常出生体重新生儿之间的关联：2013-2020 年间，共有 135,085 例供体卵母细胞胚胎移植周期，其中冷冻胚胎（42.3% 至 76.6%）、使用冷冻供体卵母细胞的新鲜胚胎（19.9% 至 68.3%）和单胚胎移植（SET）（36.4% 至 85.5%）的比例有所上升。2018-2020 年间，共有 48679 个供体卵母细胞胚胎移植周期。在新鲜（46.2%，55.9%；aRR 0.83 [95% CI 0.79-0.87]）和冷冻（41.3%，45.8%；aRR 0.94 [95% CI 0.91-0.98]）胚胎移植周期中，冷冻供体卵母细胞的活产率均低于新鲜供体卵母细胞。在单胎活产中，新鲜（77.3%，77.2%；aRR 1.01 [95% CI 0.98-1.03]）和冷冻（75.6%，75.1%；aRR 1.02 [95% CI 0.99-1.04]）胚胎移植周期的足月、正常出生体重新生儿分娩率与冷冻移植周期相似：在这项关于供体卵母细胞胚胎移植周期的全国性研究中，冷冻胚胎移植、使用冷冻卵母细胞的新鲜胚胎移植和 SET 均有所增加。虽然与新鲜卵母细胞相比，冷冻卵母细胞的活产率略有下降，但在单胎活产中，足月新生儿、正常出生体重新生儿的比率在不同的供体卵母细胞状态下相当。
{"title":"Trends and outcomes of fresh and frozen donor oocyte cycles in the United States","authors":"","doi":"10.1016/j.fertnstert.2024.07.004","DOIUrl":"10.1016/j.fertnstert.2024.07.004","url":null,"abstract":"<div><h3>Objective</h3><div>To examine trends, characteristics, and outcomes of donor oocyte embryo transfer cycles by original oocyte and resultant embryo state and determine whether oocyte state (fresh or frozen) is differentially associated with clinical pregnancy, live birth, and term, healthy birthweight neonates among singleton live births.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>National study.</div></div><div><h3>Patient(s)</h3><div>Patients undergoing donor oocyte embryo transfer cycles in the United States reporting to the National Assisted Reproductive Technology Surveillance System from 2013 to 2020<sub>.</sub></div></div><div><h3>Intervention(s)</h3><div>Original donor oocyte and resultant embryo state (fresh or frozen).</div></div><div><h3>Main Outcome Measure(s)</h3><div>Annual numbers and proportions of total donor oocyte embryo transfer cycles stratified by oocyte and embryo state and single embryo transfer cycles resulting in the live birth of term (≥37 weeks gestation), healthy birthweight (≥2,500 g) singletons during 2013–2020. Rates of live birth and term, healthy birthweight neonates among singleton live births for 2018–2020 are also reported. Relative risks examine associations between donor oocyte state and live birth and term, healthy birthweight neonates among singleton live births resulting from donor oocyte embryo transfer cycles.</div></div><div><h3>Result(s)</h3><div>From 2013 to 2020, there were 135,085 donor oocyte embryo transfer cycles, of which the proportions increased for frozen embryos (42.3%–76.6%), fresh embryos using frozen donor oocytes (19.9%–68.3%) and single embryo transfers (36.4%–85.5%). During 2018–2020, there were 48,679 donor oocyte embryo transfer cycles. Rates of live birth were lower with frozen compared with fresh donor oocytes for both fresh (46.2%, 55.9%; adjusted relative risk [aRR], 0.83; 95% confidence interval [CI], 0.79–0.87) and frozen (41.3%, 45.8%; aRR, 0.94; 95% CI, 0.91–0.98) embryo transfer cycles. Among singleton live births, rates of delivering a term, healthy birth weight neonate were similar for frozen compared with fresh donor oocyte transfer cycles among fresh (77.3%, 77.2%; aRR, 1.01; 95% CI, 0.98–1.03) and frozen (75.6%, 75.1%; aRR, 1.02; 95% CI, 0.99–1.04) embryos.</div></div><div><h3>Conclusion(s)</h3><div>In this national study of donor oocyte embryo transfer cycles, frozen embryo transfers, fresh embryo transfers using frozen oocytes, and single embryo transfers increased. Although frozen compared with fresh oocytes were associated with a slightly reduced rate of live birth, rates of term, healthy birthweight neonates among singleton live births were comparable between donor oocyte states.</div></div><div><div>Tendencias y resultados de los ciclos de ovocitos de donantes frescos y congelados en los Estados Unidos</div></div><div><h3>Objetivo</h3><div>Examinar las tendencias, características y resultados de lo","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.08.311
Sarah C. Cromack M.D., Susan C. Klock Ph.D.
{"title":"Racial and ethnic diversity among gamete donors: an urgent unmet need","authors":"Sarah C. Cromack M.D., Susan C. Klock Ph.D.","doi":"10.1016/j.fertnstert.2024.08.311","DOIUrl":"10.1016/j.fertnstert.2024.08.311","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.06.005
{"title":"Racial and ethnic disparities in wait times for donor oocytes","authors":"","doi":"10.1016/j.fertnstert.2024.06.005","DOIUrl":"10.1016/j.fertnstert.2024.06.005","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.06.019
{"title":"Longer duration to optimal endometrial thickness in women with premature ovarian insufficiency is associated with clinical pregnancy rate in donor egg cycles","authors":"","doi":"10.1016/j.fertnstert.2024.06.019","DOIUrl":"10.1016/j.fertnstert.2024.06.019","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.07.010
<div><h3>Importance</h3><div>Advances in the treatment of childhood cancer have significantly improved survival rates, with more than 80% of survivors reaching adulthood. However, gonadotoxic cancer treatments endanger future fertility, and prepubertal males have no option to preserve fertility by sperm cryopreservation. In addition, boys with cryptorchidism are at risk of compromised fertility in adulthood.</div></div><div><h3>Objective</h3><div>To investigate current evidence for male fertility restoration strategies, explore barriers to clinical implementation, and outline potential steps to overcome these barriers, a scoping review was conducted. This knowledge synthesis is particularly relevant for prepubertal male cancer survivors and boys with cryptorchidism.</div></div><div><h3>Evidence Review</h3><div>The review was conducted after the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews criteria and previously published guidelines and examined studies using human testis tissue of prepubertal boys or healthy male adults. A literature search in PubMed was conducted, and 72 relevant studies were identified, including in vivo and in vitro approaches.</div></div><div><h3>Findings</h3><div>In vivo strategies, such as testis tissue engraftment and spermatogonial stem cell transplantation, hold promise for promoting cell survival and differentiation. Yet, complete spermatogenesis has not been achieved. In vitro approaches focus on the generation of male germ cells from direct germ cell maturation in various culture systems, alongside human induced pluripotent stem cells and embryonic stem cells. These approaches mark significant advancements in understanding and promoting spermatogenesis, but achieving fully functional spermatozoa in vitro remains a challenge. Barriers to clinical implementation include the risk of reintroducing malignant cells and introduction of epigenetic changes.</div></div><div><h3>Conclusion</h3><div>Male fertility restoration is an area in rapid development. On the basis of the reviewed studies, the most promising and advanced strategy for restoring male fertility using cryopreserved testis tissue is direct testis tissue transplantation.</div></div><div><h3>Relevance</h3><div>This review identifies persistent barriers to the clinical implementation of male fertility restoration. However, direct transplantation of frozen-thawed testis tissue remains a promising strategy that is on the verge of clinical application.</div></div><div><div>Restauración de la fertilidad masculina: estrategias in vivo e in vitro basadas en células madre usando tejido testicular criopreservado: una revisión exploratoria</div></div><div><h3>Importancia</h3><div>Los avances en el tratamiento del cáncer infantil han mejorado significativamente las tasas de supervivencia, con más del 80% de los supervivientes alcanzando la edad adulta. Sin embargo, los tratamientos oncológicos gonadotóxicos ponen en peligr
{"title":"Male fertility restoration: in vivo and in vitro stem cell–based strategies using cryopreserved testis tissue: a scoping review","authors":"","doi":"10.1016/j.fertnstert.2024.07.010","DOIUrl":"10.1016/j.fertnstert.2024.07.010","url":null,"abstract":"<div><h3>Importance</h3><div>Advances in the treatment of childhood cancer have significantly improved survival rates, with more than 80% of survivors reaching adulthood. However, gonadotoxic cancer treatments endanger future fertility, and prepubertal males have no option to preserve fertility by sperm cryopreservation. In addition, boys with cryptorchidism are at risk of compromised fertility in adulthood.</div></div><div><h3>Objective</h3><div>To investigate current evidence for male fertility restoration strategies, explore barriers to clinical implementation, and outline potential steps to overcome these barriers, a scoping review was conducted. This knowledge synthesis is particularly relevant for prepubertal male cancer survivors and boys with cryptorchidism.</div></div><div><h3>Evidence Review</h3><div>The review was conducted after the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews criteria and previously published guidelines and examined studies using human testis tissue of prepubertal boys or healthy male adults. A literature search in PubMed was conducted, and 72 relevant studies were identified, including in vivo and in vitro approaches.</div></div><div><h3>Findings</h3><div>In vivo strategies, such as testis tissue engraftment and spermatogonial stem cell transplantation, hold promise for promoting cell survival and differentiation. Yet, complete spermatogenesis has not been achieved. In vitro approaches focus on the generation of male germ cells from direct germ cell maturation in various culture systems, alongside human induced pluripotent stem cells and embryonic stem cells. These approaches mark significant advancements in understanding and promoting spermatogenesis, but achieving fully functional spermatozoa in vitro remains a challenge. Barriers to clinical implementation include the risk of reintroducing malignant cells and introduction of epigenetic changes.</div></div><div><h3>Conclusion</h3><div>Male fertility restoration is an area in rapid development. On the basis of the reviewed studies, the most promising and advanced strategy for restoring male fertility using cryopreserved testis tissue is direct testis tissue transplantation.</div></div><div><h3>Relevance</h3><div>This review identifies persistent barriers to the clinical implementation of male fertility restoration. However, direct transplantation of frozen-thawed testis tissue remains a promising strategy that is on the verge of clinical application.</div></div><div><div>Restauración de la fertilidad masculina: estrategias in vivo e in vitro basadas en células madre usando tejido testicular criopreservado: una revisión exploratoria</div></div><div><h3>Importancia</h3><div>Los avances en el tratamiento del cáncer infantil han mejorado significativamente las tasas de supervivencia, con más del 80% de los supervivientes alcanzando la edad adulta. Sin embargo, los tratamientos oncológicos gonadotóxicos ponen en peligr","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.07.028
Lia Mesquita de Abreu , Manoel Roberto Franco Ramos Neto , Fábio Gomes de Matos e Souza Ph.D.
{"title":"Endometriosis and mental health: an unresolved issue","authors":"Lia Mesquita de Abreu , Manoel Roberto Franco Ramos Neto , Fábio Gomes de Matos e Souza Ph.D.","doi":"10.1016/j.fertnstert.2024.07.028","DOIUrl":"10.1016/j.fertnstert.2024.07.028","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.08.350
Anna Lena Zippl M.D., Elisabeth Reiser M.D., Beata Eva Seeber M.D., M.S.C.E.
{"title":"Reply of the authors: Endometriosis and mental health: nonfully resolved but needing greater awareness","authors":"Anna Lena Zippl M.D., Elisabeth Reiser M.D., Beata Eva Seeber M.D., M.S.C.E.","doi":"10.1016/j.fertnstert.2024.08.350","DOIUrl":"10.1016/j.fertnstert.2024.08.350","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.06.022
{"title":"Feasibility and efficacy of a subcutaneous catheter for controlled ovarian stimulation","authors":"","doi":"10.1016/j.fertnstert.2024.06.022","DOIUrl":"10.1016/j.fertnstert.2024.06.022","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.06.025
<div><h3>Importance</h3><div>Oocyte preservation for planned fertility delay, also referred to as social oocyte preservation or colloquially as “egg freezing,” has become increasingly popular in the last few decades. Previous literature has suggested that there are gaps in counseling and expectations regarding the expected thaw rates and outcomes of preserved oocytes.</div></div><div><h3>Objective</h3><div>To characterize the literature on social oocyte preservation, specifically the return rates, thaw rates, clinical pregnancy rates, and live birth rates.</div></div><div><h3>Data sources</h3><div>We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses of 7 databases (MEDLINE, EMBASE, Emcare, CINAHL, the Cochrane Library, Web of Science: Core Collection, and Scopus) until January 1, 2024. The Risk Of Bias In Non-randomized Studies of Interventions tool was used for critical appraisal.</div></div><div><h3>Study selection and synthesis</h3><div>All original human research that reported data for individuals who underwent autologous oocyte preservation for planned fertility delay (i.e., not for medical indications such as chemotherapy) was included for analysis. A meta-analysis was conducted using descriptive statistics and pooled prevalence rates. Title and abstract screening and data extraction were conducted in duplicate by 2 independent reviewers for all studies until full agreement on eligibility was achieved through consensus-based discussion.</div></div><div><h3>Main outcomes</h3><div>Return rate among those who froze oocytes for planned fertility delay, as well as live birth rate and clinical pregnancy rate among these patients.</div></div><div><h3>Results</h3><div>After screening 1,540 references, a total of 27 studies encompassing 13,724 patients were included. Follow-up ranged from 4 to 19 years, with a median follow-up time of 7 years. A total of 17,418 oocyte retrieval cycles for planned fertility delay were reported, with most individuals undergoing a single cryopreservation cycle. Overall, 10.8% of individuals returned to thaw their eggs, with an aggregate oocyte survival rate of 81.4%. The implantation rate was 44.4% and clinical pregnancy rate was 34.2%. A live birth was reported for 28.9% of individuals across all age groups who returned to thaw eggs.</div></div><div><h3>Conclusions and relevance</h3><div>Individuals should be counseled regarding the low return rates after oocyte preservation for planned fertility delay.</div></div><div><div>Tasas de retorno y resultados de embarazo después de la preservación de ovocitos para la planificación en el retraso de la fertilidad: una revisión sistemática y metanálisis</div></div><div><h3>Importancia</h3><div>La preservación de ovocitos para el retraso planificado de la fertilidad, también conocida como preservación social de ovocitos o coloquialmente como "congelación de óvulos", se ha vuelto cada vez más popular en las últimas décadas
{"title":"Return rates and pregnancy outcomes after oocyte preservation for planned fertility delay: a systematic review and meta-analysis","authors":"","doi":"10.1016/j.fertnstert.2024.06.025","DOIUrl":"10.1016/j.fertnstert.2024.06.025","url":null,"abstract":"<div><h3>Importance</h3><div>Oocyte preservation for planned fertility delay, also referred to as social oocyte preservation or colloquially as “egg freezing,” has become increasingly popular in the last few decades. Previous literature has suggested that there are gaps in counseling and expectations regarding the expected thaw rates and outcomes of preserved oocytes.</div></div><div><h3>Objective</h3><div>To characterize the literature on social oocyte preservation, specifically the return rates, thaw rates, clinical pregnancy rates, and live birth rates.</div></div><div><h3>Data sources</h3><div>We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses of 7 databases (MEDLINE, EMBASE, Emcare, CINAHL, the Cochrane Library, Web of Science: Core Collection, and Scopus) until January 1, 2024. The Risk Of Bias In Non-randomized Studies of Interventions tool was used for critical appraisal.</div></div><div><h3>Study selection and synthesis</h3><div>All original human research that reported data for individuals who underwent autologous oocyte preservation for planned fertility delay (i.e., not for medical indications such as chemotherapy) was included for analysis. A meta-analysis was conducted using descriptive statistics and pooled prevalence rates. Title and abstract screening and data extraction were conducted in duplicate by 2 independent reviewers for all studies until full agreement on eligibility was achieved through consensus-based discussion.</div></div><div><h3>Main outcomes</h3><div>Return rate among those who froze oocytes for planned fertility delay, as well as live birth rate and clinical pregnancy rate among these patients.</div></div><div><h3>Results</h3><div>After screening 1,540 references, a total of 27 studies encompassing 13,724 patients were included. Follow-up ranged from 4 to 19 years, with a median follow-up time of 7 years. A total of 17,418 oocyte retrieval cycles for planned fertility delay were reported, with most individuals undergoing a single cryopreservation cycle. Overall, 10.8% of individuals returned to thaw their eggs, with an aggregate oocyte survival rate of 81.4%. The implantation rate was 44.4% and clinical pregnancy rate was 34.2%. A live birth was reported for 28.9% of individuals across all age groups who returned to thaw eggs.</div></div><div><h3>Conclusions and relevance</h3><div>Individuals should be counseled regarding the low return rates after oocyte preservation for planned fertility delay.</div></div><div><div>Tasas de retorno y resultados de embarazo después de la preservación de ovocitos para la planificación en el retraso de la fertilidad: una revisión sistemática y metanálisis</div></div><div><h3>Importancia</h3><div>La preservación de ovocitos para el retraso planificado de la fertilidad, también conocida como preservación social de ovocitos o coloquialmente como \"congelación de óvulos\", se ha vuelto cada vez más popular en las últimas décadas","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.fertnstert.2024.06.006
Ethics Committee of the American Society for Reproductive Medicine
Medical providers have an ethical duty to disclose clinically significant errors involving gametes and embryos. Although not mandatory, disclosure of errors causing no harm or near misses is recommended. In addition, clinics should have written policies in place for reducing and disclosing errors.
Divulgación de errores médicos y eventos adversos que involucran gametas y embriones: una opinión del Comité de Ética
Los proveedores de salud tienen un deber ético de divulgar errores clínicamente significativos que involucran gametas y embriones. Aunque no es obligatorio, la divulgación de errores que no causan daño o “near misses” es recomendada. Además, las clínicas deberían tener políticas escritas establecidas para reducir y divulgar errores.
{"title":"Disclosure of medical errors and untoward events involving gametes and embryos: an Ethics Committee opinion","authors":"Ethics Committee of the American Society for Reproductive Medicine","doi":"10.1016/j.fertnstert.2024.06.006","DOIUrl":"10.1016/j.fertnstert.2024.06.006","url":null,"abstract":"<div><div>Medical providers have an ethical duty to disclose clinically significant errors involving gametes and embryos. Although not mandatory, disclosure of errors causing no harm or near misses is recommended. In addition, clinics should have written policies in place for reducing and disclosing errors.</div></div><div><div>Divulgación de errores médicos y eventos adversos que involucran gametas y embriones: una opinión del Comité de Ética</div><div>Los proveedores de salud tienen un deber ético de divulgar errores clínicamente significativos que involucran gametas y embriones. Aunque no es obligatorio, la divulgación de errores que no causan daño o “<em>near misses</em>” es recomendada. Además, las clínicas deberían tener políticas escritas establecidas para reducir y divulgar errores.</div></div>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：